Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Inovio Pharmaceuticals Reports 2016 Second Quarter Financial Results
August 8, 2016 8:00 AM EDTPLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million. Total operating expenses were $24.4 million compared to $20.4 million. The net loss attributable to common stockholders was $18.7 million, or $0.26 per share, compared to $6.2 million, or $0.09 per share.
Revenue
The increase in revenue was primarily due to an increase in development payments from our DARPA Ebola... More
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
August 4, 2016 8:02 AM EDTPLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovios regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovios product pipeline. Â Â
Dr. J. Joseph Kim, Inovios President & CEO, said, Ami has shown technical excellence and leadership in successfully moving our DNA-based... More
